无创指标动态变化对代谢相关脂肪性肝病临床结局的评估效能

艾小委; 张梦阳; 孙亚朦; 尤红

doi:10.12449/JCH260120

无创指标动态变化对代谢相关脂肪性肝病临床结局的评估效能

DOI: 10.12449/JCH260120

首都医科大学附属北京友谊医院肝病中心，北京 100050

基金项目:

北京市医院管理中心临床医学发展专项 (ZLRK202301)

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：艾小委负责整理文献及撰写文章；张梦阳、孙亚朦负责论文修订；尤红负责论文终审。

详细信息

通信作者:
尤红， youhong30@sina.com （ORCID： 0000-0001-9409-1158）

计量
- 文章访问数: 5
- HTML全文浏览量: 2
- PDF下载量: 2
- 被引次数: 0
出版历程
- 收稿日期: 2025-05-29
- 录用日期: 2025-07-25
- 出版日期: 2026-01-25

Efficacy of the dynamic changes of noninvasive indicators in evaluating clinical outcomes of metabolic associated fatty liver disease

Liver Research Center，Beijing Friendship Hospital，Capital Medical University，Beijing 100050，China

Research funding:

Beijing Hospitals Authority Clinical Medicine Development of Special Funding Support (ZLRK202301)

More Information

Corresponding author: YOU Hong， youhong30@sina.com （ORCID： 0000-0001-9409-1158）

摘要

摘要: 病理组织学检查是目前诊断代谢相关脂肪性肝病（MAFLD）的金标准，然而其为有创操作，存在风险且可行性低，因此利用无创指标评估MAFLD分期和分型成为当前研究热点。本文系统综述了不同无创指标的动态变化在反映MAFLD患者肝组织学改变及临床终点事件方面的效能。
- 非酒精性脂肪性肝病 /
- 生物标记 /
- 诊断显像 /
- 模型，统计学
Abstract: Histopathological examination is currently the gold standard for the diagnosis of metabolic associated fatty liver disease （MAFLD）； however， due to its invasiveness， high risks， and low feasibility， application of noninvasive indicators in the staging and classification of MAFLD has become a research hotspot. This article systematically reviews the efficacy of dynamic changes in various noninvasive markers in reflecting histological changes and clinical outcome events in MAFLD patients， in order to provide theoretical support for dynamic monitoring and individualized management of the disease.
- Non-alcoholic Fatty Liver Disease /
- Biomarkers /
- Diagnostic Imaging /
- Models， Statistical

HTML全文

参考文献(36)

[1]	KONG JN, ZHANG BB, SHI JP. An excerpt of clinical practice guideline of prevention and treatment of metabolic dysfunction-associated(non-alcoholic) fatty liver disease(2024 edition)[J]. J Clin Hepatol, 2024, 40( 9): 1767- 1770. DOI: 10.12449/JCH240908. 孔嘉宁, 张彬彬, 施军平.《代谢相关(非酒精性)脂肪性肝病防治指南(2024年版)》解读[J]. 临床肝胆病杂志, 2024, 40( 9): 1767- 1770. DOI: 10.12449/JCH240908.
[2]	LOU TW, YANG RX, FAN JG. The global burden of fatty liver disease: The major impact of China[J]. Hepatobiliary Surg Nutr, 2024, 13( 1): 119- 123. DOI: 10.21037/hbsn-23-556.
[3]	GE QC, LU LG. Value of liver biopsy in the diagnosis and clinical trial of non-alcoholic fatty liver disease[J]. J Clin Hepatol, 2024, 40( 11): 2288- 2292. DOI: 10.12449/JCH241124. 葛启超, 陆伦根. 肝活检在非酒精性脂肪性肝病诊断和临床试验中的价值[J]. 临床肝胆病杂志, 2024, 40( 11): 2288- 2292. DOI: 10.12449/JCH241124.
[4]	SIDDIQUI MS, YAMADA G, VUPPALANCHI R, et al. Diagnostic accuracy of noninvasive fibrosis models to detect change in fibrosis stage[J]. Clin Gastroenterol Hepatol, 2019, 17( 9): 1877- 1885.e5. DOI: 10.1016/j.cgh.2018.12.031.
[5]	HINKSON A, LALLY H, GIBSON H, et al. Meta-analysis: Enhanced liver fibrosis test to identify hepatic fibrosis in chronic liver diseases[J]. Aliment Pharmacol Ther, 2023, 57( 7): 750- 762. DOI: 10.1111/apt.17385.
[6]	GAWRIEH S, WILSON LA, YATES KP, et al. Relationship of ELF and PIIINP with liver histology and response to vitamin E or pioglitazone in the PIVENS trial[J]. Hepatol Commun, 2021, 5( 5): 786- 797. DOI: 10.1002/hep4.1680.
[7]	NIELSEN MJ, NEDERGAARD AF, SUN S, et al. The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters[J]. Am J Transl Res, 2013, 5( 3): 303- 315.
[8]	HARRISON SA, ROSSI SJ, PAREDES AH, et al. NGM282 improves liver fibrosis and histology in 12 weeks in patients with nonalcoholic steatohepatitis[J]. Hepatology, 2020, 71( 4): 1198- 1212. DOI: 10.1002/hep.30590.
[9]	LOOMBA R, LAWITZ E, MANTRY PS, et al. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial[J]. Hepatology, 2018, 67( 2): 549- 559. DOI: 10.1002/hep.29514.
[10]	ZHANG X, ZHENG MH, LIU DH, et al. A blood-based biomarker panel for non-invasive diagnosis of metabolic dysfunction-associated steatohepatitis[J]. Cell Metab, 2025, 37( 1): 59- 68.e3. DOI: 10.1016/j.cmet.2024.10.008.
[11]	LOOMBA R, NEUSCHWANDER-TETRI BA, SANYAL A, et al. Multicenter validation of association between decline in MRI-PDFF and histologic response in NASH[J]. Hepatology, 2020, 72( 4): 1219- 1229. DOI: 10.1002/hep.31121.
[12]	STINE JG, MUNAGANURU N, BARNARD A, et al. Change in MRI-PDFF and histologic response in patients with nonalcoholic steatohepatitis: A systematic review and meta-analysis[J]. Clin Gastroenterol Hepatol, 2021, 19( 11): 2274- 2283.e5. DOI: 10.1016/j.cgh.2020.08.061.
[13]	HARRISON SA, BASHIR MR, GUY CD, et al. Resmetirom(MGL-3196) for the treatment of non-alcoholic steatohepatitis: A multicentre, randomised, double-blind, placebo-controlled, phase 2 trial[J]. Lancet, 2019, 394( 10213): 2012- 2024. DOI: 10.1016/S0140-6736(19)32517-6.
[14]	KOH B, XIAO JL, NG CH, et al. Comparative efficacy of pharmacologic therapies for MASH in reducing liver fat content: Systematic review and network meta-analysis[J]. Hepatology, 2024. DOI: 10.1097/HEP.0000000000001028.
[15]	TAMAKI N, MUNAGANURU N, JUNG J, et al. Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease[J]. Gut, 2022, 71( 5): 983- 990. DOI: 10.1136/gutjnl-2021-324264.
[16]	NOGAMI A, YONEDA M, KOBAYASHI T, et al. Assessment of 10-year changes in liver stiffness using vibration-controlled transient elastography in non-alcoholic fatty liver disease[J]. Hepatol Res, 2019, 49( 8): 872- 880. DOI: 10.1111/hepr.13349.
[17]	RINELLA ME, DUFOUR JF, ANSTEE QM, et al. Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study[J]. J Hepatol, 2022, 76( 3): 536- 548. DOI: 10.1016/j.jhep.2021.10.029.
[18]	STERLING RK, DUARTE-ROJO A, PATEL K, et al. AASLD Practice Guideline on imaging-based noninvasive liver disease assessment of hepatic fibrosis and steatosis[J]. Hepatology, 2025, 81( 2): 672- 724. DOI: 10.1097/HEP.0000000000000843.
[19]	LIANG JX, AMPUERO J, NIU H, et al. An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography[J]. J Hepatol, 2023, 79( 3): 592- 604. DOI: 10.1016/j.jhep.2023.04.025.
[20]	AJMERA VH, LIU A, SINGH S, et al. Clinical utility of an increase in magnetic resonance elastography in predicting fibrosis progression in nonalcoholic fatty liver disease[J]. Hepatology, 2020, 71( 3): 849- 860. DOI: 10.1002/hep.30974.
[21]	JAYAKUMAR S, MIDDLETON MS, LAWITZ EJ, et al. Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib[J]. J Hepatol, 2019, 70( 1): 133- 141. DOI: 10.1016/j.jhep.2018.09.024.
[22]	WONG VW, ANSTEE QM, NITZE LM, et al. FibroScan-aspartate aminotransferase(FAST) score for monitoring histological improvement in non-alcoholic steatohepatitis activity during semaglutide treatment: Post-hoc analysis of a randomised, double-blind, placebo-controlled, phase 2b trial[J]. EClinicalMedicine, 2023, 66: 102310. DOI: 10.1016/j.eclinm.2023.102310.
[23]	LOOMBA R, AMANGURBANOVA M, BETTENCOURT R, et al. MASH resolution index: Development and validation of a non-invasive score to detect histological resolution of MASH[J]. Gut, 2024, 73( 8): 1343- 1349. DOI: 10.1136/gutjnl-2023-331401.
[24]	LOOMBA R, DANIEL PCN, AMANGURBANOVA M, et al. Head-to-head comparison of MASH resolution index versus FAST for noninvasive prediction of resolution of MASH on biopsy[J]. Hepatology, 2025. DOI: 10.1097/HEP.0000000000001396.
[25]	SANYAL AJ, van NATTA ML, CLARK J, et al. Prospective study of outcomes in adults with nonalcoholic fatty liver disease[J]. N Engl J Med, 2021, 385( 17): 1559- 1569. DOI: 10.1056/NEJMoa2029349.
[26]	SANYAL AJ, HARRISON SA, RATZIU V, et al. The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: Data from the simtuzumab trials[J]. Hepatology, 2019, 70( 6): 1913- 1927. DOI: 10.1002/hep.30664.
[27]	SHANG Y, AKBARI C, DODD M, et al. Association between longitudinal biomarkers and major adverse liver outcomes in patients with non-cirrhotic metabolic dysfunction-associated steatotic liver disease[J]. Hepatology, 2025, 81( 5): 1501- 1511. DOI: 10.1097/HEP.0000000000001045.
[28]	SANYAL AJ, ANSTEE QM, TRAUNER M, et al. Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis[J]. Hepatology, 2022, 75( 5): 1235- 1246. DOI: 10.1002/hep.32204.
[29]	BALKHED W, ÅBERG FO, NASR P, et al. Repeated measurements of non-invasive fibrosis tests to monitor the progression of non-alcoholic fatty liver disease: A long-term follow-up study[J]. Liver Int, 2022, 42( 7): 1545- 1556. DOI: 10.1111/liv.15255.
[30]	PETTA S, SEBASTIANI G, VIGANÒ M, et al. Monitoring occurrence of liver-related events and survival by transient elastography in patients with nonalcoholic fatty liver disease and compensated advanced chronic liver disease[J]. Clin Gastroenterol Hepatol, 2021, 19( 4): 806- 815.e5. DOI: 10.1016/j.cgh.2020.06.045.
[31]	SEMMLER G, YANG ZW, FRITZ L, et al. Dynamics in liver stiffness measurements predict outcomes in advanced chronic liver disease[J]. Gastroenterology, 2023, 165( 4): 1041- 1052. DOI: 10.1053/j.gastro.2023.06.030.
[32]	LIU WY, HUANG SS, JI HS, et al. From"burnt-out" to"burning-out": Capturing liver fat loss in patients with advanced metabolic dysfunction-associated steatotic liver disease from a dynamic perspective[J]. Gastroenterology, 2025, 169( 2): 326- 336.e4. DOI: 10.1053/j.gastro.2025.02.034.
[33]	GIDENER T, DIERKHISING RA, MARA KC, et al. Change in serial liver stiffness measurement by magnetic resonance elastography and outcomes in NAFLD[J]. Hepatology, 2023, 77( 1): 268- 274. DOI: 10.1002/hep.32594.
[34]	LIN HP, LEE HW, YIP TC, et al. Vibration-controlled transient elastography scores to predict liver-related events in steatotic liver disease[J]. JAMA, 2024, 331( 15): 1287- 1297. DOI: 10.1001/jama.2024.1447.
[35]	STERLING RK, PATEL K, DUARTE-ROJO A, et al. AASLD Practice Guideline on blood-based noninvasive liver disease assessment of hepatic fibrosis and steatosis[J]. Hepatology, 2025, 81( 1): 321- 357. DOI: 10.1097/hep.0000000000000845.
[36]	STERLING RK, ASRANI SK, LEVINE D, et al. AASLD Practice Guideline on noninvasive liver disease assessment of portal hypertension[J]. Hepatology, 2025, 81( 3): 1060- 1085. DOI: 10.1097/hep.0000000000000844.